Brief: Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects

DMK Pharmaceuticals

12/09/2022 22:29

Sept 12 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS PROVIDES AN ENROLLMENT UPDATE ON THE PHASE 2/3
STUDY OF
TEMPOL IN COVID-19 POSITIVE HIGH-RISK SUBJECTS
    * ADAMIS PHARMACEUTICALS CORP - INDEPENDENT DATA MONITORING
BOARD
TO REVIEW INTERIM DATA FROM APPROXIMATELY 200 INITIAL SUBJECTS
    * ADAMIS PHARMACEUTICALS CORP - CLINICAL TRIAL OF TEMPOL HAS
REACHED INITIAL PLANNED ENROLLMENT OF 248 SUBJECTS
    * ADAMIS PHARMACEUTICALS CORP - IF ANALYSIS OF INTERIM
CLINICAL
DATA SHOWED SIGNIFICANT EFFICACY, DSMB MAY RECOMMEND STOPPING
TRIAL
    * ADAMIS PHARMACEUTICALS CORP - IF INTERIM DATA INDICATED NO
EFFICACY ON PRIMARY ENDPOINT, DSMB WOULD LIKELY RECOMMEND
STOPPING TRIAL FOR FUTILITY

Source text for Eikon:  ID:nGNX4llR0 
Further company coverage:  ADMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))